Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 12;12:803175. doi: 10.3389/fimmu.2021.803175

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Arnold, Vital, Dass, Aslam, Rawstron, Savic, Emery and Md Yusof

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of relapse prediction based on naïve B cells and ANCA and/or CD19+ cell return. Time to relapse was compared between patients with and without naïve repopulation in (A) at 6 months and (D) at 12 months and between patients with and without ANCA and/or CD19+ cells return in (B) at 6 months and (E) at 12 months respectively using Kaplan-Meier survival analyses. Areas under the receiver operating characteristic (AUROC) were compared between the two biomarker-led retreatment strategies (C) at 6 months and (F) at 12 months postrituximab.